Aprotinin in Aortocoronary Bypass Surgery: Increased Risk of Vein-Graft Occlusion and Myocardial Infarction? Supportive Evidence from a Retrospective Study

Summary

To assess the thrombotic risk of aprotinin in aortocoronary bypass surgery, we retrospectively analyzed the results of a trial, originally designed to compare the effects of one-year treatment with various antithrombotic drugs in the prevention of vein-graft occlusion. Graft patency at one year was assessed by angiography. Myocardial infarction, thromboembolism, major bleeding, and death were clinical endpoints. Of 948 randomized patients, 42 received aprotinin, all enrolled by one of the participating centres. Occlusion rates of distal anastomoses were 20.5% in the aprotinin group and 12.7% in the non-aprotinin group (p = 0.091). The proportions of patients with occluded grafts were 44.1% versus 26.3% (p = 0.029). Perioperative myocardial infarction occurred in 14.3% and 7.0%, respectively (p = 0.12). Mean postoperative blood loss was 451 ml in the aprotinin group compared with 1039 ml in the non-aprotinin group (p <0.0001). Mean transfusion requirements were 1.1 U versus 2.1 U of red blood cells (p = 0.004).

Aprotinin decreases blood loss and transfusion requirement. Our data suggest that this benefit may be associated with a reduction of graft patency and an increased risk of myocardial infarction.

• References

• 1 Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; ii: 1289-1291
• 2 Fraedrich G, Weber C, Bernard C, Hettwer A, Schlosser V. Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin – preliminary results. Thorac Cardiovasc Surg 1989; 37: 89-91
• 3 Dietrich W, Barankay A, Dilthey G, Henze R, Niekau E, Sebening F, Richter JA. Reduction of homologous blood requirement in cardiac surgery by intraoperative aprotinin application – clinical experience in 152 cardiac surgical patients. Thorac Cardiovasc Surg 1989; 37: 92-98
• 4 Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364-372
• 5 Alajmo F, Calamai G, Pema AM, Melissano G, Pretelli P, Palmarini MF, Carbonetto F, Noferi D, Boddi V, Palminiello A, Vacari M. High-dose aprotinin: hemostatic effects in open heart operations. Ann Thorac Surg 1989; 48: 536-539
• 6 Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-1038
• 7 Fuster V, Badimon L, Badimon JJ, Adams PC, Turitto V, Chesebro JH. Drugs interfering with platelet functions: mechanisms and clinical relevance. In: Thrombosis and Haemostasis 1987 Verstraete M, Vermylen J, Lijnen R, Arnout J. eds. Leuven: Leuven University Press; 1987: 349-418
• 8 Bidstrup BP, Underwood SR, Sapsford RN, Streets EM. Effect of aprotinin (Trasylol) on aorto-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993; 105: 147-153
• 9 Havel M, Grabenwoger F, Schneider J, Laufer G, Wollenek G, Owen A, Simon P, Teufelsbauer H, Wolner E. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994; 107: 807-810
• 10 Lemmer JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, Schaff HV, Tatooles CJ, Rumberger JA. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994; 107: 543-553
• 11 van der Meer J, Hillege HL, Kootstra GJ, Ascoop CAPL, Mulder BJM, Pfisterer M, van Gilst WH, Lie KI. Prevention of one-year vein-graft occlusion after aortocoro-nary-bypass surgery: A comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet 1993; 342: 257-264
• 12 Blauhut B, Gross C, Necek S, Doran JE, Späth P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-967
• 13 Samama ChM, Mazoyer E, Bruneval P, Ciostek P, Bonnin Ph, Bonneau M, Roussi J, Baillart O, Pignaud G, Viars P, Caen JP, Drouet LO. Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study. Thromb Haemost 1994; 71: 663-669
• 14 van der Meer J, Hillege HL, van Gilst WH, Brutel de la Rivière A, Dunselman PHJM, Fidler V, Kootstra GJ, Mulder BJM, Pfisterer M, Lie KI. A comparison of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery: no difference in one year occlusion rates and clinical outcome. Circulation 1994; 90: 2367-2374